Sign in
BCLI Stock Price, Chart, Stats & News
Brainstorm Cell Therapeutics Inc.
Save
Brainstorm Cell Therapeutics Inc. (BCLI) does not currently pay a dividend.
–
Market cap
–
Current P/E
–
Forward P/E
BCLI chart
1M
3M
1Y
5Y
Loading chart...
Fundamentals
Gross margin | 68.43% |
Operating margin | -1283.63% |
Pretax margin | -1277.50% |
Net margin | -1277.50% |
Effective tax rate | – |
ROA | -1243.81% |
ROE | 212.08% |
D/E | 0.40x |
Interest coverage ratio | -27.52x |
BCLI valuation
P/E | – |
P/S | 11.70x |
P/B | 12.05x |
P/CF | -1.36x |
P/FCF | -1.36x |
P/OCF | -1.36x |
PEG | -0.05x |
EV multiple | -0.90x |
About
Brainstorm Cell Therapeutics Inc. (BCLI) is a biotechnology firm dedicated to the development and commercialization of personalized, autologous cellular therapies. These innovative treatments are specifically designed to address neurodegenerative diseases. At the heart of its strategy is the proprietary NurOwn cell therapy platform.
Similar securities
Based on sector and market capitalization
Report issue